Ecrins Therapeutics is a privately held Biotech company specialized in the discovery and development of innovative oncology drugs, to treat and cure patients suffering from deadly and debilitating diseases. Using its original drug candidate discovery platform, the company has created a pipeline of high-value projects.
Year of creation: 2010
Line of business: Biotechnology & Pharma
Institut Curie: Behind the technology
Ecrins Therapeutics put in place an original and disruptive drug discovery engine allowing the discovery and development of patentable molecules directed against new therapeutic targets. The company has developed a unique concept based on the creation of cellular models of human cancer. Ecrins creates cells with a well-defined cancer-related phenotype (physical trait), then uses these cell models of human cancer to find small molecules or biologicals (therapeutic antibodies) which can reverse the target cancer hallmark.
EcrinsTherapeutics’ main program is ET-D5 – a small molecule drug candidate that the company discovered and now develops for several oncology indications.
Ecrins Therapeutics aims to discover and develop novel anti-cancer molecules into efficacious drugs to treat human and animal (dogs, cats) cancer.